BARDA Archives - Page 2 of 2 - EverGlade Consulting

BARDA

Medical Countermeasures through BARDA

BARDA Announces Request for Project Proposal for On-Demand Manufacturing

The Biomedical Advanced Research and Development Authority (BARDA) is spearheading this effort with its innovative On-Demand Manufacturing program. This initiative is designed to revolutionize the production and distribution of MCMs by developing portable, continuous, and end-to-end manufacturing systems.

BARDA Announces Request for Project Proposal for On-Demand Manufacturing Read More »

BARDA Issues Amendment 4 to BAA for Medical Countermeasures R&D

BARDA Issues Amendment 4 to BAA for Medical Countermeasures R&D 

BARDA has recently unveiled significant updates to its BAA, emphasizing a more refined and responsive approach to public health preparedness. Amendment 4 introduces crucial changes to the Areas of Interest designed to align BARDA’s efforts with the evolving landscape of global health threats.

BARDA Issues Amendment 4 to BAA for Medical Countermeasures R&D  Read More »

BARDA Issues Amendment 3 to BAA for Medical Countermeasures R&D

BARDA Issues Amendment 3 to BAA for Medical Countermeasures R&D 

The Biomedical Advanced Research and Development Authority (BARDA) has recently unveiled significant updates to its Broad Agency Announcement (BAA), emphasizing a more refined and responsive approach to public health preparedness. Amendment 3, in particular, brings crucial changes to the Areas of Interest (AOIs) that are designed to align BARDA’s efforts with the evolving landscape of global health threats. 

BARDA Issues Amendment 3 to BAA for Medical Countermeasures R&D  Read More »

Covid Research

EverGlade Consulting Lands ModeX Therapeutics Up to $168 Million in BARDA Funding

EverGlade Consulting, a national consulting firm, has helped ModeX Therapeutics successfully secure up to $168 million in funding through a contract with the Biomedical Advanced Research and Development Authority (“BARDA”) to develop novel multispecific antibodies against viral infectious disease threats. How Funding Will Be Used The $168 million in BARDA funding will advance research and clinical trials for multispecific

EverGlade Consulting Lands ModeX Therapeutics Up to $168 Million in BARDA Funding Read More »

BARDA Post-Award represented with a digital drawing of virus and microscope

Effective Post-Award Management of a BARDA Contract

The Biomedical Advanced Research and Development Authority (BARDA) plays a pivotal role in the United States’ preparedness for public health emergencies. BARDA contracts support the development, procurement, and deployment of medical countermeasures critical for safeguarding public health during crises. Once awarded a BARDA contract, effective post-award management becomes paramount to ensure the successful execution of

Effective Post-Award Management of a BARDA Contract Read More »

medical countermeasures development

Guide to BARDA Funding Broad Agency Announcement Update

The Biomedical Advanced Research and Development Authority (BARDA), a USG agency that operates within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has recently released a new, modernized Broad Agency Announcement (BAA) with the goal of enhancing efficiency, improving responsiveness, and reducing

Guide to BARDA Funding Broad Agency Announcement Update Read More »

Antibodies attacking virus cell for BARDA Funding Guide

A Guide to BARDA Funding

A Guide to BARDA Funding: Application Process, Financial and Technical Requirements A Comprehensive Guide to BARDA Funding The Biomedical Advanced Research and Development Authority, commonly known as BARDA, has played a pivotal role in safeguarding public health in the United States and beyond. Since its inception, BARDA has bolstered the country’s preparedness and response capabilities

A Guide to BARDA Funding Read More »

Scroll to Top
A yellow lab flask with Donald Trump hair and a red tie.

Webinar: R&D Funding in Life Sciences: What's Ahead in Trump 2.0?

Join us on Jan 15, 2025, at 12:00pm ET for a deep dive into the future of R&D Funding in Life Sciences.